Thermo Fisher said that it received notice that TRC Capital made an unsolicited mini-tender offer to purchase up to 1 million shares of its stock at $181.75 per share.
The offer of $402 per share was made in connection with Abbott's acquisition of Alere, which was completed on Tuesday.
Abbott's tender offer to purchase all outstanding shares of Alere's Series B convertible perpetual preferred stock at $402 per share is now scheduled to expire on Oct. 3.
The tender offer, which is being extended to allow additional time for the consummation of Abbott's acquisition of Alere, could expire at the end of August.
LabCorp plans to acquire all of Sequenom's outstanding stock for $2.40 per share.
Agilent received notice of an unsolicited mini-tender offer by TRC Capital to purchase up to 2.5 million shares of Agilent's shares at a discount to market price.
Foundation Medicine shareholders tendered a total of nearly 18.8 million shares of common stock.
Roche said that based on preliminary results, Foundation Medicine shareholders tendered a total of 17.5 million shares, not including 1.9 million shares that were tendered by notice of guaranteed delivery.
Roche will acquire a majority stake in Foundation Medicine and directly invest in R&D.
The offer for 15.6 million shares of Foundation's common stock at $50 per share has been extended to midnight EST at the end of the day April 6.
An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.
Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.